Teglicar

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Teglicar (ST-1326) is a potent, selective and reversible inhibitor of liver carnitine palmitoyl-transferase 1 (L-CPT1) with IC50 of 0.68 uM, Ki of 0.36 uM.

Teglicar (ST-1326) is a potent, selective and reversible inhibitor of liver carnitine palmitoyl-transferase 1 (L-CPT1) with IC50 of 0.68 uM, Ki of 0.36 uM; displays an extraordinarily high selectivity (39-fold) toward the liver isoform over the heart isoform (muscle-CPT1;M-CPT1); reduces gluconeogenesis and improves glucose homeostasis, shows antiketotic and antidiabetic activity in diabetic db/db mice; also inhibits fatty acid oxidation associated with cell growth arrest, mitochondrial damage, and apoptosis induction in leukemia cell lines; orally active.Diabetes Phase 2 Discontinued

ST-1326;ST1326

Others

Other Targets

Other Targets

Metabolic Disease

Diabetes

250694-07-6

399.62

C22H45N3O3

>98% (HPLC)

——

CCCCCCCCCCCCCCNC(=O)NC(CC(=O)[O-])C[N+](C)(C)C

(R)-4-Trimethylammonio-3-[(tetradecylcarbamoyl)amino]butyrate

(-20℃)

With Ice Pack

≥ 2 years